ClinicalTrials.gg
Not yet recruitingNCT07212582ALBUSUpdated Nov 19, 2025

Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study)

A Phase 3 interventional study of Human Albumin 20% Solution and Standard Care (in control arm) in Critical Illness and Septic Shock, sponsored by Mahidol University. Not yet recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Primary conditionShock, SepticRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Shock, Septic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Mahidol University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Shock, Septic by Mahidol University — 6 open to participants now, 6 under way, 1 of them phase 3. Shock, Septic · Mahidol University.

Planned enrollment
2nd of 12
304 · median 145
Started
2025
with 1 other
Phase 3
Only one
of the 14
Registered
14th of 14
by date

Among the 14 studies in Shock, Septic by Mahidol University, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 3, and was the 14th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

6 of the 14 studies in Shock, Septic by Mahidol University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Shock, Septic by Mahidol University, or all of them as a file.
02

Study summary

This study will test whether giving human albumin to keep the blood albumin level above 3.5 g/dL, in addition to standard care, improves survival in patients with surgical septic shock. Septic shock is a life-threatening complication of infection that often requires urgent surgery and intensive care. Current treatment guidelines recommend intravenous fluids and medications to support blood pressure, but the best type of fluid is still uncertain.

Human albumin is a natural protein in the blood that helps maintain fluid balance and has anti-inflammatory effects. Previous studies suggest that low albumin levels are linked with worse outcomes in septic patients, and that albumin infusion might improve recovery, but results are mixed and evidence in surgical septic shock patients is lacking.

In this randomized controlled trial, adult patients with surgical septic shock admitted to the surgical intensive care unit will be randomly assigned to receive either standard care alone or standard care plus 20% human albumin solution for up to 3 days. The main outcome is survival at 28 days. Secondary outcomes include length of ICU and hospital stay, need for dialysis, ventilator-free days, vasopressor-free days, fluid balance, gastrointestinal recovery, and adverse reactions.

The results of this study will help determine whether targeted albumin replacement is beneficial in critically ill surgical patients with septic shock and could guide future fluid resuscitation strategies.

Read the detailed description

This is a single-center, randomized, open-label, controlled trial designed to evaluate the effect of targeted albumin replacement in adult patients with surgical septic shock. The study will be conducted in the Surgical Intensive Care Unit at Siriraj Hospital, Bangkok, Thailand.

Eligible patients are those aged 18 years or older admitted with surgical septic shock, defined as suspected or proven surgical infection requiring an operation or surgical intervention within 48 hours, and persisting shock despite adequate initial fluid resuscitation. After informed consent, participants will be randomized in a 1:1 ratio, using block randomization, to one of two groups:

Control group: Standard sepsis management according to international guidelines, including source control, broad-spectrum antibiotics, intravenous crystalloids, vasopressors, and other adjunctive therapies as required.

Intervention group: Standard care plus intravenous 20% human albumin solution, given for up to 72 hours, with dosing guided by serum albumin levels to maintain concentrations above 3.5 g/dL.

The primary endpoint is 28-day all-cause mortality. Secondary endpoints include length of ICU and hospital stay, ventilator-free days, vasopressor-free days, 7-day cumulative fluid balance, acute kidney injury requiring renal replacement therapy, recovery of gastrointestinal function, and adverse reactions.

The planned sample size is 304 patients (152 per arm), which provides 80% power to detect a relative risk reduction of 40% in 28-day mortality (from 35% to 20%) with two-sided alpha of 0.05, accounting for 10% attrition.

Data will be analyzed primarily on an intention-to-treat basis. Interim analysis is planned after 50% enrollment to assess safety and efficacy. Both frequentist and Bayesian approaches will be applied, including logistic regression to adjust for baseline imbalances if needed.

This trial will provide evidence on whether maintaining serum albumin above 3.5 g/dL with human albumin infusion improves survival and clinical outcomes in critically ill patients with surgical septic shock.

03

Conditions studied

  • Critical Illness
  • Septic Shock

Browse trials for

Keywords

  • human albumin
  • fluid resuscitation
  • colloids
  • Surgical Intensive Care Unit (SICU)
  • surgical septic shock
  • Randomized Controlled Trial
04

In context

Shock, Septic Reclassified

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

This study's planned enrollment of 304 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

Mahidol University is the lead sponsor of 750 studies on the registry; 123 are open to participants now.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years) admitted to the surgical intensive care unit (SICU).
  • Diagnosis or suspicion of surgical infection requiring surgery or surgical intervention within 48 hours of ICU admission.
  • Septic shock, defined as:
  • Mean arterial pressure \<65 mmHg after adequate fluid resuscitation or requirement for vasopressors to maintain mean arterial pressure (MAP) ≥65 mmHg for at least 1 hour, and
  • Evidence of organ dysfunction (Sequential Organ Failure Assessment (SOFA) score increase ≥2) or signs of tissue hypoperfusion (serum lactate >2 mmol/L, oliguria \<0.5 mL/kg/h >2 h, or clinical evidence of poor peripheral perfusion).

Exclusion criteria

Exclusion Criteria:

  • Refusal of consent or do-not-resuscitate (DNR) status.
  • More than 24 hours since meeting inclusion criteria.
  • to albumin infusion or history of severe allergic reaction to albumin.
  • Conditions where albumin infusion is already indicated (e.g., large-volume paracentesis >5 L, hepatorenal syndrome, spontaneous bacterial peritonitis, plasmapheresis, cirrhosis, nephrotic syndrome, protein-losing enteropathy, severe burns, post-cardiac or thoracic surgery).
  • Evidence of fluid overload or pulmonary edema (bilateral crepitations, chest infiltrates consistent with pulmonary edema, Central Venous Pressure >15 mmHg, Pulmonary Artery Occlusion Pressure [PAOP] >18 mmHg, or N-terminal pro-B-type Natriuretic Peptide [NT-proBNP] >900 pg/mL)
  • End-stage renal disease or receiving chronic renal replacement therapy.
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
304 participants (estimated)

Study arms

  • Active comparator
    Standard Care

    Patients in this group will receive standard sepsis management according to international guidelines. This includes source control, intravenous broad-spectrum antibiotics, balanced crystalloids, vasopressors, and adjunctive therapies (e.g., corticosteroids, thiamine, ventilatory and renal support) as clinically indicated. Albumin may be given if separate indications arise (e.g., perioperative use, severe hypoalbuminemia \<2.5 g/dL with capillary leakage), at the discretion of the treating physician.

    Other: Standard Care (in control arm)

  • Experimental
    Standard Care Plus Albumin

    Patients in this group will receive standard sepsis management as above, plus intravenous 20% human albumin solution. On admission, 50 mL of 20% albumin will be infused over 2 hours, followed by additional doses for up to 72 hours, titrated according to daily serum albumin levels. The target is to maintain serum albumin \>3.5 g/dL: 1 vial every 12 hours if 2.5-3.4 g/dL, or every 6 hours if \<2.5 g/dL. Infusion will be withheld in the presence of fluid overload, pulmonary edema, or severe hypernatremia.

    Drug: Human Albumin 20% Solution · Other: Standard Care (in control arm)

Interventions

  • DrugAlbumins humanStudies of Albumins humanAlbumins human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous 20% human albumin solution (50 mL per vial). In the experimental arm, patients receive 50 mL over 2 hours on admission, followed by additional doses for up to 72 hours, titrated to maintain serum albumin \>3.5 g/dL. If albumin is 2.5-3.4 g/dL, 1 vial every 12 hours is given; if \<2.5 g/dL, 1 vial every 6 hours is given. Infusion is withheld if there is fluid overload, pulmonary edema, or severe hypernatremia.

  • OtherStandard Care (in control arm)

    Patients in this group will receive standard sepsis management according to international guidelines. This includes source control, intravenous broad-spectrum antibiotics, balanced crystalloids, vasopressors, and adjunctive therapies (e.g., corticosteroids, thiamine, ventilatory and renal support) as clinically indicated. Albumin may be given if separate indications arise (e.g., perioperative use, severe hypoalbuminemia \<2.5 g/dL with capillary leakage), at the discretion of the treating physician.

07

What researchers measure

Primary outcomes

  1. 28-Day All-Cause Mortality

    Mortality from any cause within 28 days of ICU admission, assessed by review of hospital records and/or telephone follow-up if the patient is discharged before Day 28.

    Time frame: 28 days after randomization

Secondary outcomes

  1. ICU Length of Stay

    Number of days from ICU admission to ICU discharge. For participants who die in the ICU, length of stay will be recorded up to the date of death.

    Time frame: From ICU admission until ICU discharge or death in the ICU, assessed for up to 90 days.

  2. Hospital Length of Stay

    Number of days from hospital admission to hospital discharge. For participants who die in the hospital, length of stay will be recorded up to the date of death.

    Time frame: From hospital admission until hospital discharge or in-hospital death, assessed for up to 90 days.

  3. Vasopressor-Free Days

    Number of days alive and without vasopressor therapy during the first 28 days. Patients who die before Day 28 will be assigned zero vasopressor-free days.

    Time frame: 28 days after randomization

  4. 7-Day Cumulative Fluid Balance

    Net fluid balance (total fluid input minus total output) recorded daily and summed across the first 7 days of ICU stay.

    Time frame: First 7 days after randomization

  5. Acute Kidney Injury Requiring Renal Replacement Therapy

    Incidence of renal replacement therapy initiation for acute kidney injury, determined from ICU and hospital records.

    Time frame: Up to 28 days after randomization

  6. Adverse Reactions

    Incidence of adverse reactions related to albumin infusion, including allergic or anaphylactic reactions, pulmonary edema, or electrolyte disturbances.

    Time frame: Up to 28 days after randomization

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because of institutional policies at Siriraj Hospital that restrict the transfer of identifiable patient-level data outside the institution. Only aggregate, de-identified data will be reported in publications and presentations. Researchers interested in collaboration may contact the study investigators to discuss potential data analyses consistent with local regulations.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2029, 48 months later.

Of 45 non-industry phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's planned 48 months is above that.

Counting every sponsor, half of 46 studies reached it within 42 months; a quarter within 16 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Oct 8, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07212582
Lead sponsor
Mahidol University
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 19, 2025

Study contacts

Nuanprae Kitisin, MD
Contact
nuanprae.kit@mahidol.ac.th
+66896767706

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumins human

Start the discussion